



Prostatype Genomics AB enters into cooperation with leading actor in the prostate cancer area

– Agreement on marketing and R&D cooperation enhancing market position short- and long-term

Prostatype Genomics AB (“Prostatype Genomics”) has signed a cooperation agreement with Proteomedix AG (“Proteomedix”), a Zurich based science-driven company that has an approved product in the field of prostate cancer. The product is complementary to Prostatype®, the gene based prognostic tool developed and marketed by Prostatype Genomics.

Used in different stages of the clinical process of prostate cancer, Prostatype® and the complementary product this will offer unique decision support for patients and physicians.

The marketing agreement is non-exclusive and covers many of Prostatype Genomics’ prioritized markets, such as Germany, Italy, Sweden, Switzerland and the UK.

R&D collaboration

As an important future-looking part of the cooperation, Prostatype Genomics and Proteomedix will establish a Research & Development cooperation, working to further enhance the clinical value by looking into synergies between the tests. The collaboration will strengthen Prostatype on the commercial as well as on the R&D-side. The expected activities within the framework of the cooperation include, among other things, execution of a pilot study as well as clinical validation studies, several new distribution agreements in the EMEA and quicker market entries in EMEA and US by expansion of commercial organisations.

Fredrik, Persson, CEO of Prostatype Genomics, comments: *“Working together with our new partner is the definition of a win-win! We are both growing our market footprints, and the wider offering will make us more attractive for payers, labs and physicians. Looking beyond the sales and marketing cooperation, I am very excited about starting up the R&D cooperation. Combining these two leading technologies could result in something completely new. To maximize the benefits of this exciting cooperation we will look into the possibilities to raise additional funding shortly”*.

This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 26-08-2021 21:15 CET.

Fredrik Persson

Media enquiries
fredrik.persson@prostatypegenomics.com

Certified Advisor

Svensk Kapitalmarknadsgranskning AB, 011-32 30 732, ca@skmg.se

About Prostatype® and the P-score

Prostatype Genomics P-score is an algorithm containing 3-genes signature and three clinical parameters. By combining traditional clinical risk factors with prognostic biomarkers derived from the original prostate biopsy the Prostatype® test system offer a P-score, greatly improving prognostic evaluation, providing important input in the treatment assessment.